In 2016, the FDA approved the semi-quantitative PCR-based Roche cobas® EGFR mutation test v2 as a companion diagnostic test, using ctDNA, for the detection of EGFR-sensitizing mutations in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.